GO
Loading...

Bristol-Myers Squibb performance was staggering: Analyst

Thursday, 23 Jan 2014 | 3:30 PM ET

As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.